{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T17:09:24Z","timestamp":1772903364297,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["NU50CK000651"],"award-info":[{"award-number":["NU50CK000651"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajicjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Infection Control"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajic.2025.08.022","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:30:28Z","timestamp":1756362628000},"page":"1282-1291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of a mRNA vaccine booster dose against COVID-19 among Oregon health care personnel, January 2021 to June 2023"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0598-9762","authenticated-orcid":false,"given":"Madysen","family":"Schreiber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie L.S.","family":"Ocampo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Dusko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0244-7458","authenticated-orcid":false,"given":"Eric W.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajic.2025.08.022_bib1","unstructured":"Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine emergency use authorization; 2020. Accessed June 10, 2024. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/pfizer-biontech-covid-19-vaccine."},{"key":"10.1016\/j.ajic.2025.08.022_bib2","unstructured":"Food and Drug Administration. Moderna COVID-19 vaccine emergency use authorization; 2020. Accessed June 10, 2024. \u3008https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/\u3009."},{"key":"10.1016\/j.ajic.2025.08.022_bib3","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.15585\/mmwr.mm6949e1","article-title":"The Advisory Committee on Immunization Practices\u2019 interim recommendation for allocating initial supplies of COVID-19 vaccine \u2014 United States, 2020","volume":"69","author":"Dooling","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ajic.2025.08.022_bib4","doi-asserted-by":"crossref","unstructured":"U.S. Food and Drug Administration. FDA authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations; 2021. Accessed June 10, 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations.","DOI":"10.47287\/cen-09931-buscon1"},{"key":"10.1016\/j.ajic.2025.08.022_bib5","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3390\/vaccines10091425","article-title":"COVID-19 vaccine mandates for healthcare professionals in the United States","volume":"10","author":"Rao","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.ajic.2025.08.022_bib6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/21650799211049811","article-title":"\"Still on the Fence\": a mixed methods investigation of COVID-19 vaccine confidence among health care providers","volume":"70","author":"Choi","year":"2022","journal-title":"Workplace Health Saf"},{"key":"10.1016\/j.ajic.2025.08.022_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.5344","article-title":"Trends in health care worker intentions to receive a COVID-19 vaccine and reasons for hesitancy","volume":"4","author":"Meyer","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ajic.2025.08.022_bib8","article-title":"COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA","volume":"6","author":"Vilches","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.ajic.2025.08.022_bib9","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1093\/cid\/ciac454","article-title":"Durability of severe acute respiratory syndrome Coronavirus 2 messenger RNA booster vaccine protection against Omicron among healthcare workers with a vaccine mandate","volume":"76","author":"Richterman","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajic.2025.08.022_bib10","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1056\/NEJMoa2106599","article-title":"Effectiveness of mRNA Covid-19 vaccine among U.S. health care personnel","volume":"385","author":"Pilishvili","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajic.2025.08.022_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajic.2025.08.022_bib12","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-021-01410-w","article-title":"Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom","volume":"27","author":"Pritchard","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ajic.2025.08.022_bib13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ajic.2025.08.022_bib14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.15585\/mmwr.mm7018e1","article-title":"Effectiveness of Pfizer-BioNTech and moderna vaccines against COVID-19 among hospitalized adults aged \u226565 years - United States, January-March 2021","volume":"70","author":"Tenforde","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ajic.2025.08.022_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad457","article-title":"Effectiveness of a messenger RNA vaccine booster dose against Coronavirus disease 2019 among US healthcare personnel, October 2021\u2013July 2022","volume":"10","author":"Plumb","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ajic.2025.08.022_bib16","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.vaccine.2024.03.019","article-title":"Sociodemographic and occupational characteristics associated with early and continued COVID-19 vaccine uptake among healthcare personnel: Monroe County, NY","volume":"42","author":"Russ","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.ajic.2025.08.022_bib17","unstructured":"Centers for Disease Control and Prevention. Project to address COVID-19 among healthcare workers. April 17, 2024. Accessed June, 2024. https:\/\/www.cdc.gov\/healthcare-associated-infections\/php\/haic-eip\/covid-19.html."},{"key":"10.1016\/j.ajic.2025.08.022_bib18","unstructured":"Oregon Health Authority. OHA vaccine phasing. Oregon Health Authority. April 6, 2021. Accessed June, 2024. https:\/\/sharedsystems.dhsoha.state.or.us\/DHSForms\/Served\/le3527A.pdf."},{"key":"10.1016\/j.ajic.2025.08.022_bib19","unstructured":"Oregon Bureau of Labor & Industries. COVID vaccinations and the workplace. COVID-19 For Workers; 2021. Accessed June, 2024. https:\/\/secure.sos.state.or.us\/oard\/viewSingleRule.action?ruleVrsnRsn=302917."},{"key":"10.1016\/j.ajic.2025.08.022_bib20","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.15585\/mmwr.mm7044e2","article-title":"The Advisory Committee on Immunization Practices\u2019 interim recommendations for additional primary and booster doses of COVID-19 vaccines \u2014 United States, 2021","volume":"70","author":"Mbaeyi","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ajic.2025.08.022_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ije\/dyac207","article-title":"Estimation of vaccine effectiveness using the screening method","volume":"52","author":"Farrington","year":"2023","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ajic.2025.08.022_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/ije\/dyac013","article-title":"Commentary: estimation of vaccine effectiveness using the screening method","volume":"52","author":"Flannery","year":"2023","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ajic.2025.08.022_bib23","unstructured":"Centers for Disease Control and Prevention. COVID Data Tracker. U.S. Department of Health and Human Services, CDC; Accessed June 27, 2024. https:\/\/covid.cdc.gov\/covid-data-tracker."},{"key":"10.1016\/j.ajic.2025.08.022_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.15585\/mmwr.mm7107e2","volume":"71","author":"Ferdinands","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ajic.2025.08.022_bib25","doi-asserted-by":"crossref","first-page":"931","DOI":"10.15585\/mmwr.mm7129e1","article-title":"Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2\/BA.2.12.1 sublineages predominated - VISION Network, 10 States, December 2021-June 2022","volume":"71","author":"Link-Gelles","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ajic.2025.08.022_bib26","article-title":"Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study","volume":"9","author":"Tartof","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.ajic.2025.08.022_bib27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S2213-2600(22)00354-X","article-title":"Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study","volume":"11","author":"Tartof","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ajic.2025.08.022_bib28","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","article-title":"Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants","volume":"28","author":"Tseng","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ajic.2025.08.022_bib29","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajic.2025.08.022_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2022.106700","article-title":"COVID-19 vaccines: considering sex differences in efficacy and safety","volume":"115","author":"Jensen","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.ajic.2025.08.022_bib31","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ajic.2025.08.022_bib32","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(23)00058-0","article-title":"Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study","volume":"23","author":"Chemaitelly","year":"2023","journal-title":"Lancet Infect Dis"}],"container-title":["American Journal of Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196655325005607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196655325005607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:02:53Z","timestamp":1772841773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196655325005607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0196655325005607"],"URL":"https:\/\/doi.org\/10.1016\/j.ajic.2025.08.022","relation":{},"ISSN":["0196-6553"],"issn-type":[{"value":"0196-6553","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of a mRNA vaccine booster dose against COVID-19 among Oregon health care personnel, January 2021 to June 2023","name":"articletitle","label":"Article Title"},{"value":"American Journal of Infection Control","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajic.2025.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}